← Back to Screener
Arbutus Biopharma Corporation Common Stock (ABUS)
Price$4.68
Favorite Metrics
Price vs S&P 500 (26W)3.19%
Price vs S&P 500 (4W)-0.41%
Market Capitalization$875.74M
All Metrics
Book Value / Share (Quarterly)$0.40
P/TBV (Annual)2.38x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-28.80%
Cash Flow / Share (Quarterly)$-0.21
Price vs S&P 500 (YTD)-9.50%
Net Profit Margin (TTM)-237.88%
EPS (TTM)$-0.18
10-Day Avg Trading Volume1.59M
EPS Excl Extra (TTM)$-0.18
Revenue Growth (5Y)15.30%
EPS (Annual)$-0.17
ROI (Annual)-41.87%
Net Profit Margin (5Y Avg)-528.86%
Cash / Share (Quarterly)$0.48
Revenue Growth QoQ (YoY)-33.23%
ROA (Last FY)-35.41%
Revenue Growth TTM (YoY)128.21%
EBITD / Share (TTM)$-0.19
ROE (5Y Avg)-56.00%
Operating Margin (TTM)-270.96%
Cash Flow / Share (Annual)$-0.21
P/B Ratio11.44x
P/B Ratio (Quarterly)12.08x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)61.15x
Net Interest Coverage (TTM)-26.93x
ROA (TTM)-32.48%
EV / EBITDA (TTM)27.59x
EPS Incl Extra (Annual)$-0.17
Current Ratio (Annual)15.73x
Quick Ratio (Quarterly)15.47x
3-Month Avg Trading Volume1.97M
52-Week Price Return36.59%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.12
P/S Ratio (Annual)62.18x
Asset Turnover (Annual)0.15x
52-Week High$5.10
Operating Margin (5Y Avg)-554.99%
EPS Excl Extra (Annual)$-0.17
CapEx CAGR (5Y)-20.96%
Tangible BV CAGR (5Y)23.90%
26-Week Price Return7.18%
Quick Ratio (Annual)15.47x
13-Week Price Return-0.44%
Total Debt / Equity (Annual)0.04x
Current Ratio (Quarterly)15.73x
Enterprise Value$861.176
Revenue / Share Growth (5Y)-4.20%
Asset Turnover (TTM)0.14x
Book Value / Share Growth (5Y)-18.95%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-237.88%
Cash / Share (Annual)$0.48
3-Month Return Std Dev56.17%
Net Income / Employee (TTM)$-1
ROE (Last FY)-43.75%
Net Interest Coverage (Annual)-37.59x
EPS Basic Excl Extra (Annual)$-0.17
P/FCF (TTM)42.64x
Receivables Turnover (TTM)7.30x
Total Debt / Equity (Quarterly)0.04x
EPS Incl Extra (TTM)$-0.18
Receivables Turnover (Annual)7.30x
ROI (TTM)-40.42%
P/S Ratio (TTM)62.18x
Pretax Margin (5Y Avg)-526.58%
Revenue / Share (Annual)$0.07
Tangible BV / Share (Annual)$1.12
Price vs S&P 500 (52W)6.76%
Year-to-Date Return-6.86%
5-Day Price Return4.19%
EPS Normalized (Annual)$-0.17
ROA (5Y Avg)-42.36%
Net Profit Margin (Annual)-237.88%
Month-to-Date Return-0.44%
Cash Flow / Share (TTM)$-0.46
EBITD / Share (Annual)$-0.19
Operating Margin (Annual)-270.96%
LT Debt / Equity (Annual)0.04x
ROI (5Y Avg)-54.10%
LT Debt / Equity (Quarterly)0.04x
EPS Basic Excl Extra (TTM)$-0.18
P/TBV (Quarterly)2.38x
P/B Ratio (Annual)12.08x
Pretax Margin (TTM)-237.88%
Book Value / Share (Annual)$0.40
Price vs S&P 500 (13W)-1.13%
Beta0.69x
P/FCF (Annual)26.62x
Revenue / Share (TTM)$0.07
ROE (TTM)-42.39%
52-Week Low$2.94
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ABUSArbutus Biopharma Corporation Common Stock | 62.18x | 128.21% | — | — | $4.68 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Arbutus Biopharma is a clinical-stage biopharmaceutical company developing combination therapies for hepatitis B aimed at achieving a functional cure. Key pipeline candidates include imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor. The company leverages proprietary Lipid Nanoparticle (LNP) delivery technology to optimize therapeutic efficacy.